[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 48 of about 48

Advertisement
4. Miyata A, Fujii S, Kikuchi T, Kibata M: [Acute myelocytic leukemia (M0) in an elderly patient with relapsed granulocytic sarcoma (M7) of bone during the second period of complete remission 5 years after onset]. Nihon Ronen Igakkai Zasshi; 2003 Mar;40(2):176-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myelocytic leukemia (M0) in an elderly patient with relapsed granulocytic sarcoma (M7) of bone during the second period of complete remission 5 years after onset].
  • He had suffered from acute myelocytic leukemia (AML: M0) in November 1994 and achieved the first complete remission (CR) then.
  • Histological examination of the biopsied bone tissue showed a diffuse proliferation of round cells with medium-sized or large nuclei.
  • Although CD56 had not been examined initially, he might have been had myeloid/NK cell precursor acute leukemia and CD41 might be acquired later in the course of the disease.
  • It is known that AML M0, M7 and myeloid/NK cell precursor acute leukemia have poor prognoses, nevertheless he survived for 6 years.
  • It may be that intensive and repeated chemotherapy for AML can obtain excellent outcome in the elderly cases in good systemic condition and with favourable prognostic factors.
  • [MeSH-major] Bone Neoplasms / pathology. Leukemia, Myeloid, Acute / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Aged. Humans. Male. Remission Induction


5. Gorin NC: Autologous stem cell transplantation in acute lymphocytic leukemia. Stem Cells; 2002;20(1):3-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in acute lymphocytic leukemia.
  • Autologous stem cell transplantation (ASCT) as well as allogeneic stem cell transplantation and conventional chemotherapy (CT) are less effective at treating acute lymphocytic leukemia (ALL) than acute myelocytic leukemia (AML).
  • Statistics from the European Group for Blood and Marrow Transplantation reveal a transplant-related mortality at 5 years of 11% +/- 1%, a relapse incidence of 60% +/- 2%, and a leukemia-free survival (LFS) and overall survival (OS) of 36% +/- 2% and 42% +/- 2%, respectively in 1,366 adults autografted in first remission (CR1).
  • In contrast, multicentric and single-institution studies have found better results in adults autografted in CR1, with LFS at 5 years from 46% to 64%, possible efficacy of marrow in vitro purging with mafosfamide (LFS 52%), and improvement in outcome with additional measures post-ASCT, such as maintenance chemotherapy (LFS 57%).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Child. Disease-Free Survival. Europe. Humans. Registries. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11796917.001).
  • [ISSN] 1066-5099
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


6. Neudorf S, Sanders J, Kobrinsky N, Alonzo TA, Buxton AB, Gold S, Barnard DR, Wallace JD, Kalousek D, Lange BJ, Woods WG: Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood; 2004 May 15;103(10):3655-61
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival.
  • In Children's Cancer Group (CCG) study 2891, patients who were recently diagnosed with acute myelocytic leukemia (AML) were assigned randomly to standard- or intensive-timing induction chemotherapy.
  • Patients in first complete remission (CR1) and who had a human leukocyte antigen (HLA)-identical, related donor or a donor disparate at a single class I or II locus were nonrandomly assigned to receive a bone marrow transplant (BMT) by using oral busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg).
  • Disease-free survival (DFS) at 6 years was 67% and 42% for recipients of intensive- and standard-timing induction therapies, respectively.
  • Multivariate analysis showed that receiving intensive-timing induction therapy (P =.027) and having no hepatomegaly at diagnosis (P =.009) was associated with favorable DFS, and grades 3 and 4 acute GVHD were associated with inferior DFS.
  • Multivariate analysis showed that grades 1 or 2 GVHD (P =.008) and no hepatomegaly at diagnosis (P =.014) were associated with improved relapse-free survival (RFS).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bone Marrow Transplantation / methods. Graft vs Leukemia Effect. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Hepatomegaly. Humans. Infant. Infant, Newborn. Male. Methotrexate / administration & dosage. Remission Induction / methods. Risk Factors. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14751924.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 02971; United States / NCI NIH HHS / CA / CA 03750; United States / NCI NIH HHS / CA / CA 07306; United States / NCI NIH HHS / CA / CA 10382; United States / NCI NIH HHS / CA / CA 11796; United States / NCI NIH HHS / CA / CA 17829; United States / NCI NIH HHS / CA / CA 26044; United States / NCI NIH HHS / CA / CA 26126; United States / NCI NIH HHS / CA / CA 27678; United States / NCI NIH HHS / CA / CA 29013; United States / NCI NIH HHS / CA / CA 29314; United States / NCI NIH HHS / CA / CA 36015; United States / NCI NIH HHS / CA / CA 42764; United States / NCI NIH HHS / CA / CA 61833; United States / NCI NIH HHS / CA / CA 69274; United States / NCI NIH HHS / CA / CA 79726; United States / NCI NIH HHS / CA / CA 79753
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Zheng X, Ravatn R, Lin Y, Shih WC, Rabson A, Strair R, Huberman E, Conney A, Chin KV: Gene expression of TPA induced differentiation in HL-60 cells by DNA microarray analysis. Nucleic Acids Res; 2002 Oct 15;30(20):4489-99
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) is a potent inducer of differentiation in human promyelocytic leukemia cells.
  • Recently, TPA has been successfully administered to patients with myelocytic leukemia and has produced therapeutic effects that led to temporary remission.
  • These studies demonstrated the potential efficacy of TPA in cancer chemotherapy.
  • We now seek to understand the biological effects and molecular mechanisms of differentiation in response to TPA treatment in leukemia cells by expression profiling using DNA microarray.

  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Life Sci. 1999 Aug 15;55(10):1230-54 [10487205.001]
  • [Cites] Adv Second Messenger Phosphoprotein Res. 1993;28:143-52 [8398396.001]
  • [Cites] Mol Cell Biol. 1993 Feb;13(2):841-51 [8423806.001]
  • [Cites] J Biol Chem. 1993 Feb 25;268(6):4078-84 [8440699.001]
  • [Cites] Stem Cells. 2000;18(3):157-65 [10840068.001]
  • [Cites] Mol Cell Biol Res Commun. 2000 Jan;3(1):60-5 [10683319.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24767-75 [10825181.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):331-6 [11099034.001]
  • [Cites] Trends Immunol. 2001 Feb;22(2):83-7 [11286708.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 [11390274.001]
  • [Cites] Cell Death Differ. 2001 Aug;8(8):794-800 [11526432.001]
  • [Cites] Cell Mol Life Sci. 2001 Jul;58(8):1105-12 [11529502.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S37-43 [11684441.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):270-8 [11600884.001]
  • [Cites] Oncol Res. 2000;12(9-10):419-27 [11697820.001]
  • [Cites] Mol Carcinog. 2001 Dec;32(4):195-205 [11746831.001]
  • [Cites] Leuk Res. 1984;8(4):611-6 [6540831.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(19):7316-9 [3463970.001]
  • [Cites] Nucleic Acids Res. 1987 Jul 10;15(13):5181-97 [3037489.001]
  • [Cites] Blood. 1987 Nov;70(5):1233-44 [3311197.001]
  • [Cites] Blood. 1988 Apr;71(4):899-906 [3162693.001]
  • [Cites] Cancer Res. 1988 May 15;48(10):2744-8 [3162823.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jun;85(11):3713-7 [3375238.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1261-8 [2537146.001]
  • [Cites] J Biol Chem. 1989 Jul 25;264(21):12394-401 [2501306.001]
  • [Cites] Cell. 1990 Feb 23;60(4):547-55 [1967983.001]
  • [Cites] EMBO J. 1990 Nov;9(11):3631-9 [1976511.001]
  • [Cites] Ann N Y Acad Sci. 1991;628:199-211 [2069303.001]
  • [Cites] J Clin Invest. 1991 Aug;88(2):571-7 [1864967.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1067-70 [1319842.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Aug 31;187(1):79-85 [1325796.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10355-9 [1332047.001]
  • [Cites] Cell Growth Differ. 1992 Oct;3(10):739-45 [1445803.001]
  • [Cites] Science. 1993 Mar 19;259(5102):1763-6 [7681221.001]
  • [Cites] Exp Cell Res. 1993 Aug;207(2):407-12 [8344388.001]
  • [Cites] J Cell Sci. 1993 Aug;105 ( Pt 4):1165-72 [8227206.001]
  • [Cites] J Biol Chem. 1994 Feb 11;269(6):4327-31 [8308000.001]
  • [Cites] Cell. 1994 Feb 25;76(4):747-60 [8124713.001]
  • [Cites] Cell. 1994 Mar 25;76(6):1025-37 [8137421.001]
  • [Cites] J Biol Chem. 1994 Sep 16;269(37):23230-5 [8083228.001]
  • [Cites] Biochemistry. 1994 Nov 29;33(47):14109-14 [7947821.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2212-21 [7718893.001]
  • [Cites] Genomics. 1995 Jan 1;25(1):335-7 [7774951.001]
  • [Cites] Hum Mol Genet. 1995 May;4(5):869-78 [7633447.001]
  • [Cites] Biochem J. 1995 Nov 15;312 ( Pt 1):205-13 [7492314.001]
  • [Cites] Leuk Res. 1995 Oct;19(10):699-705 [7500645.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2095-147 [8630372.001]
  • [Cites] Biochem Biophys Res Commun. 1996 May 24;222(3):821-6 [8651929.001]
  • [Cites] Dev Biol. 1996 Jul 10;177(1):309-22 [8660897.001]
  • [Cites] Differentiation. 1996 Mar;60(1):59-66 [8935929.001]
  • [Cites] DNA Cell Biol. 1996 Dec;15(12):1025-38 [8985116.001]
  • [Cites] J Biol Chem. 1997 Feb 14;272(7):4391-7 [9020161.001]
  • [Cites] FEBS Lett. 1997 Sep 1;414(1):146-52 [9305749.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7407-16 [9372971.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):1026-31 [9422764.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5357-61 [9560280.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5362-5 [9560281.001]
  • [Cites] J Biol Chem. 1998 May 8;273(19):11583-8 [9565575.001]
  • [Cites] Leuk Res. 1998 Jun;22(6):537-47 [9678720.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1957-66 [9731053.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15412-7 [9860982.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2907-12 [10077610.001]
  • [Cites] Virology. 1999 May 10;257(2):330-40 [10329544.001]
  • [Cites] Semin Cell Dev Biol. 1999 Apr;10(2):189-95 [10441072.001]
  • (PMID = 12384596.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA080826; United States / NCI NIH HHS / CA / CA 80826
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Neoplasm; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ PMC137144
  •  go-up   go-down


8. Yamamura R, Yamane T, Aoyama Y, Nakamae H, Makita K, Shima E, Ohta K, Inoue T, Sakamoto H, Hino M: Development of chronic myelocytic leukemia after chemotherapy for malignant fibrous histiocytoma. Acta Haematol; 2003;109(3):141-4
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of chronic myelocytic leukemia after chemotherapy for malignant fibrous histiocytoma.
  • Although arterial infusion chemotherapy (pirarubicin hydrochloride and carboplatin) was given, no tumor shrinkage was observed, and surgery was therefore performed to remove the tumor.
  • Thereafter, the patient received autologous peripheral blood stem cell transplantation with high-dose chemotherapy (combination of ifosphamide, carboplatin and etoposide) as pretreatment.
  • An increase in the peripheral leukocyte count was noted 56 months after the diagnosis of MFH was made.
  • Chronic myelocytic leukemia (CML) was therefore diagnosed.
  • MFH was in a state of complete remission.
  • The clinical course of this patient strongly suggests that this was a case of treatment-related CML that developed after chemotherapy for MFH.
  • Treatment-related malignant blood diseases are known to include acute myelocytic leukemia and myelodysplastic syndrome, but reports of treatment-related CML are rare, although there have been some cases of treatment-related CML occurring several years after pretreatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Histiocytoma, Benign Fibrous / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / chemically induced. Maxillary Sinus Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12714824.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Hirayama Y, Sakamaki S, Takayanagi N, Tsuji Y, Sagawa T, Chiba H, Matsunaga T, Niitsu Y: [Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival]. Gan To Kagaku Ryoho; 2003 Aug;30(8):1113-8
Hazardous Substances Data Bank. L-Leucine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival].
  • Ubenimex was concurrently administered to 18 elderly patients with acute myelocytic leukemia (AML), and a chemotherapy protocol was prepared corresponding to patient age and organ disorders.
  • The dose-reduced protocol of the Japan Adult Leukemia Study Group (JALSG) '95 or aclarubicin 14 mg/m2 day 1-4, cytosine arabinoside 15 mg/m2 day 1-14, granulocyte colony stimulating factor (G-CSF) 150 micrograms/body day 1-14 (CAG therapy) were administered.
  • In addition, ubenimex 30 mg/day was administered orally after induction of remission.
  • As per the JALSG protocol for dose reduction when organ disorder is absent, 85% and 70% of the dose were administered to the patients aged 65-69 years and 70-74 years, respectively.
  • For patients aged 75 years or more and patients with mild disorders of the heart, kidney, and liver, CAG therapy was administered.
  • As a result, the complete remission (CR) rate was 67%, and the three-year survival rate was 32%.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Leucine / administration & dosage. Leucine / analogs & derivatives. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Aclarubicin / administration & dosage. Age Factors. Aged. Aged, 80 and over. Cytarabine / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Remission Induction. Survival Rate

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12938265.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 74KXF8I502 / Aclarubicin; GMW67QNF9C / Leucine; I0J33N5627 / ubenimex
  •  go-up   go-down


10. Bergmann OJ, Christiansen M, Laursen I, Bang P, Hansen NE, Ellegaard J, Koch C, Andersen V: Low levels of mannose-binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy. Eur J Haematol; 2003 Feb;70(2):91-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low levels of mannose-binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy.
  • PURPOSE: To estimate the clinical significance of low serum concentrations of mannose-binding lectin (MBL) in patients with acute myeloid leukaemia (AML) during initial cancer chemotherapy.
  • PATIENTS AND METHODS: 80 consecutive, newly diagnosed, and unselected AML patients (age 18-77 yr) undergoing remission induction chemotherapy.
  • MAIN FINDINGS: Low levels of serum MBL (<1,000 microg/L) were found in 16/80 patients at diagnosis.
  • In the remaining 64 patients, MBL concentrations were significantly higher than in controls and showed only a slight rise during the period of antineoplastic chemotherapy with its associated infectious complications.
  • [MeSH-major] Fever / etiology. Infection / etiology. Leukemia, Myeloid / complications. Mannose-Binding Lectin / blood
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Female. Humans. Incidence. Male. Middle Aged. Morbidity. Prospective Studies. Remission Induction / methods. Survival Rate

  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12581190.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Mannose-Binding Lectin
  •  go-up   go-down


11. Moon HW, Shin S, Kim HY, Kim YR, Cho HI, Yoon SS, Park S, Kim BK, Chun H, Kim HC, Park CJ, Min YH, Lee DS: Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia. Leukemia; 2006 Aug;20(8):1408-13
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia.
  • We have experienced a number of cases of AML1/ETO+ acute myelogenous leukemia that showed remission based on bone marrow (BM) morphological criteria, but that revealed clonal abnormalities in most cells by fluorescence in situ hybridization (FISH).
  • The malignant cells were differentiated and considered mature cells after granulocyte-colony stimulating factor (G-CSF) treatment.
  • To clarify the possible mechanisms underlying this phenomenon, we investigated the expression levels of G-CSFR in AML cells with AML1/ETO rearrangement by flow cytometry and real-time polymerase chain reaction (PCR).
  • In addition, the G-CSFR gene was more highly expressed in AML1/ETO+ cells than in AML1/ETO- cells by real-time PCR.
  • This study reveals that cases showing remission after treatment with G-CSF mostly had leukemia with AML1/ETO rearrangement.
  • We recommend that remission should be confirmed by FISH, because malignant clones can be differentiated and masked in morphological examination or chromosome test, especially for AML with AML1/ETO rearrangement.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Rearrangement. Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791271.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human; 0 / Receptors, Granulocyte Colony-Stimulating Factor; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


12. Iyer RV, Sait SN, Matsui S, Block AW, Barcos M, Slack JL, Wetzler M, Baer MR: Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome. Cancer Genet Cytogenet; 2004 Jan 1;148(1):29-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome.
  • Massive hyperdiploidy (>50 chromosomes) and tetraploidy (4n) are rare cytogenetic abnormalities in myelocytic malignancies, and their significance is unknown.
  • We report on 11 patients with acute myelocytic leukemia (AML) and two patients with a myelodysplastic syndrome (MDS) with massive hyperdiploidy (10 patients) or tetraploidy (3 patients) seen at our institution over a 12-year period.
  • Only one AML patient had a previous MDS, and no patient had therapy-related disease.
  • Eleven patients received induction chemotherapy, but only four achieved complete remission.
  • We conclude that massive hyperdiploidy and tetraploidy are infrequent abnormalities in AML and MDS, are seen primarily in de novo disease in older male patients and are associated with a low remission rate and short survival.
  • Massive hyperdiploidy and tetraploidy define a prognostically unfavorable cytogenetic group in de novo AML.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Myelodysplastic Syndromes / genetics. Polyploidy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome


13. Xu RR, Cao F, Liu ZX: [Clinical observation on treatment of acute myelocytic leukemia by supplementing qi, nourishing yin and clearing heat principle]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 May;24(5):411-4
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation on treatment of acute myelocytic leukemia by supplementing qi, nourishing yin and clearing heat principle].
  • OBJECTIVE: To observe the clinical efficacy of TCM with supplementing Qi, nourishing Yin and clearing heat principle (SQNYCH) combined with chemotherapy in treating myelocytic leukemia.
  • To the treated group, SQNYCH was applied as the basic treatment, with combined chemotherapeutic protocol, using DA, HA and IA, to induce remission, and to the M3 patients, all-trans retinoic acid and arsenic trioxide were given.
  • RESULTS: In the treated group 49 patients (72.1%) were completely remitted, 9 (13.2%) partially remitted and the total remission rate being 85.3%, which was significantly different from that in the control group.
  • After treatment, the blood and bone marrow picture were obviously improved in both groups, but the increase of hemoglobin and platelet were better in the treated group than in the control group (P < 0.05 or P < 0.01).
  • CONCLUSION: Application of SQNYCH principle in treating acute myelocytic leukemia could elevate the clinical efficacy, which is of great value in clinical practice.

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15199624.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


14. Douer D: Acute promyelocytic leukemia. Curr Treat Options Oncol; 2000 Apr;1(1):31-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia.
  • The treatment of acute promyelocytic leukemia (APL) is different from other subtypes of acute myelocytic leukemia (AML).
  • All trans-retinoic acid (ATRA) is an essential component of the standard remission induction for all newly diagnosed APL patients.
  • Remission induction with ATRA and chemotherapy given concurrently appears to be associated with fewer relapses.
  • With further consolidation chemotherapy without high-dose cytosine arabinoside, the disease-free survival rate can reach 70% to 80%, and many of these patients are cured, more so than in any other AML subtype.
  • APL is especially sensitive to anthracyclines, which should be included in the chemotherapy cycles at a higher dose than in other AML subtypes.
  • Maintenance with low-dose chemotherapy (oral daily 6-mercaptopurine with weekly methotrexate) or ATRA further improves the long-term outcome.
  • New approaches are also available for relapsing patients, although the optimal treatment is unknown.
  • Patients who did not receive oral ATRA in first relapse can be treated with this agent, as can first relapsing patients who have been off the drug for more than 1 year.
  • Because of poor remission rates, ATRA should not be used in patients with second or subsequent relapses (whether ATRA was given in the past), in patients with relapses early after ATRA discontinuation, or in patients relapsing while on ATRA therapy.
  • Because arsenic trioxide is still experimental and not yet widely available, patients who are unlikely to respond to ATRA or who unsuccessfully undergo ATRA reinduction should be treated with chemotherapy.
  • Patients in second or subsequent remission induced with ATRA or chemotherapy should receive consolidation chemotherapy.
  • When arsenic trioxide is used for reinduction, the drug should be continued for several cycles; however, adding consolidation chemotherapy might improve the results.
  • Because it is unknown whether APL in second or subsequent remission is curable with salvage therapy, allogeneic hematopoietic stem cell transplantation is often considered for patients with a human leukocyte antigen (HL-A)-identical sibling and autologous transplantation when a donor does not exist.
  • However, compared with the new treatments, the role of transplantation for relapse is unclear.
  • In first remission, there is no role for transplantation.
  • A new liposomal formulation of intravenous ATRA is being investigated and seems effective in late first relapses, and it may be able to induce and maintain first remissions in selected patients without chemotherapy.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Hematopoietic Stem Cell Transplantation. Humans. Survival Rate. Treatment Outcome. Tretinoin / therapeutic use

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1991 Sep 15;78(6):1413-9 [1884013.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1717-28 [7655004.001]
  • [Cites] Leuk Res. 1994 Aug;18(8):587-96 [8065160.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4300-10 [9596679.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1321-5 [9242568.001]
  • [Cites] Blood. 1992 Jan 15;79(2):299-303 [1309668.001]
  • [Cites] Blood. 1998 Aug 1;92(3):784-9 [9680345.001]
  • [Cites] Blood. 1997 Aug 1;90(3):967-73 [9242525.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):78-85 [9440726.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Blood. 2000 Jan 1;95(1):90-5 [10607690.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):591-613 [10468848.001]
  • [Cites] Blood. 1995 May 15;85(10):2643-53 [7742522.001]
  • [Cites] Eur J Haematol. 1990 Apr;44(4):257-60 [2188854.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2225-9 [10498592.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):2100-4 [8481912.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1913-21 [2230879.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2712-8 [9763554.001]
  • [Cites] Blood. 1993 Oct 1;82(7):2175-81 [8400267.001]
  • [Cites] Blood. 1996 May 1;87(9):3650-4 [8611689.001]
  • [Cites] Bone Marrow Transplant. 1994 Aug;14(2):293-8 [7994245.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):483-90 [9053469.001]
  • [Cites] Blood. 1999 May 15;93(10 ):3167-215 [10233871.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1390-8 [8695858.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2230-5 [10498593.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2138-42 [1559217.001]
  • [Cites] Blood. 1994 Jul 15;84(2):666-7 [8025292.001]
  • (PMID = 12057059.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  • [Number-of-references] 34
  •  go-up   go-down


15. Sanborn RE, Blanke CD: Gastrointestinal stromal tumors and the evolution of targeted therapy. Clin Adv Hematol Oncol; 2005 Aug;3(8):647-57
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumors and the evolution of targeted therapy.
  • Gastrointestinal stromal tumors (GISTs) historically have differed from other soft-tissue sarcomas in demonstrating a particularly grim prognosis.
  • GISTs have an extraordinarily high rate of recurrence after surgical resection and are highly resistant to radiation and standard chemotherapy.
  • The discovery that constitutive activation of the c-kit gene drives malignant behavior in GISTs exposed a weakness that was soon exploited through the application of the novel targeted therapy imatinib, a small-molecule tyrosine kinase inhibitor of Bcr-Abl, KIT, and the platelet-derived growth factor receptor-alpha and -beta.
  • Imatinib had shown unparalleled results in patients with advanced chronic myelogenous leukemia (remission rates approaching 98%), and the first GIST patients treated with imatinib demonstrated dramatic response rates unseen with other therapeutic modalities.
  • The gains that have been made in the treatment of GIST through the use of imatinib have helped to open the door to a new era of development of targeted therapeutic agents in oncology.
  • Whether this new era of targeted therapy will provide the same advances in more common malignancies will be determined only through the ongoing application and development of clinical trials.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Proto-Oncogene Proteins c-kit / metabolism. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Clinical Trials as Topic. Combined Modality Therapy / methods. Combined Modality Therapy / trends. Drug Delivery Systems / methods. Drug Delivery Systems / trends. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / metabolism. Humans. Imatinib Mesylate. Receptor, Platelet-Derived Growth Factor alpha / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor beta / metabolism

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167051.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 108
  •  go-up   go-down


16. Watanabe I, Yakushijin Y, Sakai I, Yasukawa M, Fujita S: [Granulocytic sarcoma developing in lymph nodes]. Rinsho Ketsueki; 2002 May;43(5):378-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was initially diagnosed as having non-Hodgkin lymphoma, diffuse large cell type, Ann Arbor stage IV, and transferred to our hospital for chemotherapy.
  • Flow cytometric analysis of the left axillary lymph node cells derived from a biopsy specimen showed that in addition to lymphoid surface markers (CD5, 7, 21), myeloid surface markers (CD11b, 33, 34) were also positive.
  • The diagnosis of malignant lymphoma was therefore confirmed.
  • The patient, was treated with THP-COP therapy, which proved very effective.
  • On basis of these findings and the previous results of flow cytometry, we changed the diagnosis from malignant lymphoma to granulocytic sarcoma.
  • THP-COP therapy was continued, and complete remission was achieved.
  • Two months later, however, the patient developed acute myelocytic leukemia (AML M1) and received DCP therapy, but he died of pneumonia.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Humans. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / pathology. Male. Neoplasms, Second Primary / etiology. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12096491.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


17. Dłuzniewska A, Balwierz W, Balcerska A, Chybicka A, Kamieńska E, Karolczyk G, Karpińska-Derda I, Krawczuk-Rybak M, Kowalczyk JR, Lewandowska D, Maciejka-Kapuścińska L, Kołtano S, Malinowska I, Matysiak M, Mikołajczyk M, Mizia-Malarz A, Muszyńska-Rosłan K, Niedźwiedzki M, Pohorecka J, Sikorska-Fic B, Sobol G, Sońta-Jakimczyk D, Tomaszewska R, Urasiński T, Wachowiak J, Wieczorek M, Wójcik B, Wysocki M: [Treatment failure in children with acute myelocytic leukemia: over 25-year experience of Polish Pediatric Leukemia/Lymphoma Study Group with four consecutive unified treatment protocols for childhood acute myelocytic leukemia]. Przegl Lek; 2010;67(6):366-70
Genetic Alliance. consumer health - Acute Myelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment failure in children with acute myelocytic leukemia: over 25-year experience of Polish Pediatric Leukemia/Lymphoma Study Group with four consecutive unified treatment protocols for childhood acute myelocytic leukemia].
  • Four consecutive intensive unified regimens (BFM-AML-83, PGP-AML 94, PGP-AML 98 AML-BFM 2004 Interim) for acute myelocytic leukemia (AML) have been conducted by the Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG) since 1983.
  • Complete remission rates were: 71.4%, 67.5%, 81.4% and 87% in consecutive periods, respectively.
  • Despite continuous improvement of the treatment results, the number of failures have remained too high, but the pattern have changed in the following way: Early deaths (from diagnosis to 15 day of treatment) decreased only in the fourth period to 3%.
  • Deaths in remission decreased from 10% in first and second period to 3.5% at present.
  • Number of non responders increased between first and second period from 6% to 18%, later decreased to 8.2% at present.
  • These trends e.g. decrease of early death and treatment related mortality reflect both the better efficacy of antileukemic treatment and the improvement of supportive care.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Poland / epidemiology. Remission Induction. Survival Rate. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344763.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


18. Anak S, Saribeyoglu ET, Bilgen H, Unuvar A, Karakas Z, Devecioglu O, Agaoglu L, Gedikoglu G: Allogeneic versus autologous versus peripheral stem cell transplantation in CR1 pediatric AML patients: a single center experience. Pediatr Blood Cancer; 2005 Jun 15;44(7):654-9
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Treatment of childhood acute myelocytic leukemia (AML) in first remission, is still evolving.
  • PROCEDURE: Out of 81 pediatric patients with AML in first CR, 67 were biologically randomized for allogeneic (n = 31), autologous (n = 20), or peripheral stem cell transplant (n = 16) after completing consolidation treatment, with the remaining (n = 11) dropping out or receiving chemotherapy.
  • CONCLUSION: In pediatric AML patients without a donor, autologous BMT or autologous PBSCT appears to be an effective treatment option with low transplant related mortality especially in less privileged countries where the chemotherapy only results are still low.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Myeloid / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15700262.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gokcan MK, Batikhan H, Calguner M, Tataragasi AI: Unilateral hearing loss as a presenting manifestation of granulocytic sarcoma (chloroma). Otol Neurotol; 2006 Jan;27(1):106-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 34-year-old female patient with acute myeloid leukemia on remission admitted because of sudden hearing loss in her right ear for 10 days.
  • After confirmation of her audiometric findings with auditory brainstem responses, the patient was put on a treatment regimen for sudden hearing loss.
  • RESULTS: On the second day of treatment, she developed ipsilateral facial paralysis, hoarseness caused by ipsilateral vocal fold paralysis, and nystagmus.
  • As increased intracranial pressure symptoms developed subsequently, subtotal tumor resection was performed.
  • However, the patient was lost, with Cushing's triad at the second postoperative month during postoperative chemotherapy.
  • Despite the rarity of such a case, we would like to emphasize that leukemia must be kept in mind as an etiologic factor in sensorineural hearing loss and suggest that complete blood count and temporal bone imaging be routinely obtained.
  • [MeSH-major] Cerebellar Neoplasms / complications. Cerebellar Neoplasms / diagnosis. Cerebellopontine Angle. Hearing Loss, Sudden / etiology. Sarcoma, Myeloid / complications. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Adult. Auditory Threshold. Evoked Potentials, Auditory, Brain Stem / physiology. Facial Paralysis / etiology. Female. Humans. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / therapy. Magnetic Resonance Imaging. Treatment Outcome. Vocal Cord Paralysis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371856.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


23. Fujii S, Miyata A, Kikuchi T, Kibata M: [An elderly case of acute myelocytic leukemia complicated with bleeding gastric angiodysplasia, successfully treated with topical endoscopic polidocanol injection]. Nihon Ronen Igakkai Zasshi; 2004 May;41(3):334-8
Hazardous Substances Data Bank. DODECYL ALCOHOL, ETHOXYLATED .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An elderly case of acute myelocytic leukemia complicated with bleeding gastric angiodysplasia, successfully treated with topical endoscopic polidocanol injection].
  • A 72-year-old man with acute myelocytic leukemia (AML) suffered relapsing massive bleeding from gastric angiodysplasia.
  • Remission induction therapy by BHAC/DM regimen failed.
  • While considering subsequent regimens, massive hematemesis from a solitary gastric angiodysplasia developed.
  • In April, after re-remission induction by CAG regimen, hematemesis from the same lesion reccurred.
  • After achievement of complete remission by CAG therapy, he was treated on an outpatient basis.
  • In July, his AML relapsed and he was treated mainly by transfusion therapy.
  • In September, hematemesis recurred resulting in hemostasis with the same procedure.
  • In this case, topical injection of polidocanol was an effective procedure for the massive bleeding from it even in an elderly patient with the complication of thrombocytopenia due to AML.
  • [MeSH-major] Angiodysplasia / complications. Gastrointestinal Hemorrhage / drug therapy. Leukemia, Myeloid, Acute / complications. Polyethylene Glycols / administration & dosage. Stomach Diseases / complications


24. Zhang JH, Zheng YC, Wang YX, Zhang JY, Liu ZG: Laboratory study on near-tetraploid acute myelogenous leukemia of childhood. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr;11(4):263-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laboratory study on near-tetraploid acute myelogenous leukemia of childhood.
  • Near-tetraploidy is a rare cytogenetic abnormality in myelocytic malignancies in children, and its significance is unknown.
  • To investigate the characteristics of near-tetraploidy in a child with acute myelogenous leukemia (AML-M4), bone marrow smears were prepared for morphological analysis.
  • The patient was given four cycles of chemotherapy, and finally achieved clinical remission.
  • However, the duration achieving the remission in the child was longer than AML children with normal karyotype.
  • It is believed that near-tetraploid karyotype may have a great significance to the therapy and prognosis.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Polyploidy
  • [MeSH-minor] Bone Marrow Cells / pathology. Child. DNA, Neoplasm / analysis. Female. Humans. Immunophenotyping. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374808.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


25. Stadtmauer EA: Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia. Semin Oncol; 2002 Jun;29(3 Suppl 7):47-51
Hazardous Substances Data Bank. HISTAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia.
  • Despite successful chemotherapeutic remission induction, most patients with acute myeloid leukemia still are destined to die from recurrent and refractory disease.
  • Strategies to prolong remission and improve survival include high-dose chemotherapy, autologous or allogeneic stem cell transplantation, and other immunotherapeutic approaches.
  • The addition of histamine to IL-2-based cytokine therapies has resulted in enhanced in vitro cytotoxic T-cell and natural killer-cell function and has allowed for the development of lower, and thus, less toxic, IL-2 regimens.
  • Preliminary studies of this combination in patients with acute myeloid leukemia in remission suggest improved survival with tolerable toxicity.
  • The strategy for implementation of IL-2-based immunotherapy in patients with acute myeloid leukemia is reviewed.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12068389.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Interleukin-2; 820484N8I3 / Histamine
  • [Number-of-references] 52
  •  go-up   go-down


26. Yoshida C, Suzukawa K, Katsura Y, Shimizu S, Mukai HY, Hasegawa Y, Imagawa S, Kojima H, Nagasawa T: T-cell acute lymphoblastic leukemia with add(1)(p36) and del(12)(p11) following acute myelocytic leukemia with partial deletion of 9p. Cancer Genet Cytogenet; 2004 Apr 1;150(1):62-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell acute lymphoblastic leukemia with add(1)(p36) and del(12)(p11) following acute myelocytic leukemia with partial deletion of 9p.
  • We describe the case of a 40-year-old man whose disease was initially diagnosed as acute myelocytic leukemia.
  • The patient achieved remission with chemotherapy, but relapsed shortly afterwards with an acute T-cell lymphoblastic leukemia.
  • At relapse the leukemia cells had additional abnormalities such as add(1)(p36) and del(12)(p11).
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 9 / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] Adult. Fatal Outcome. Genes, p16 / physiology. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Neoplasm Recurrence, Local / genetics. Remission Induction


27. Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, Edan G: Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry; 2008 Jan;79(1):52-6
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
  • OBJECTIVE: To report the long term effectiveness and safety of mitoxantrone as induction therapy in patients with aggressive relapsing-remitting MS, and to assess treatment response factors.
  • Relapses, Expanded Disability Status Scale (EDSS) and drug safety were assessed every 6 months for up to at least 5 years.
  • Within 6 months after induction, 73 patients received maintenance therapy (mitoxantrone every 3 months (n = 21); interferon beta (n = 25); azathioprine (n = 15); methotrexate (n = 7); glatiramer acetate (n = 5)).
  • In the longer term, the ARR reduction was sustained (0.29-0.42 for up to 5 years), the median time to the first relapse was 2.8 years and disability remained improved after 5 years.
  • Younger age and lower EDSS score at the start of mitoxantrone treatment were predictive of better treatment response.
  • One patient was diagnosed with acute myeloid leukaemia (remission 5 years after diagnosis).
  • CONCLUSION: Mitoxantrone monthly for 6 months as induction therapy followed by maintenance treatment showed sustained clinical benefit for up to 5 years with an acceptable adverse events profile in patients with aggressive relapsing-remitting MS.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Mitoxantrone / therapeutic use. Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Azathioprine / therapeutic use. Brain / pathology. Demography. Disability Evaluation. Drug Therapy, Combination. Female. Follow-Up Studies. Glatiramer Acetate. Humans. Immunosuppressive Agents / therapeutic use. Interferon-beta / therapeutic use. Magnetic Resonance Imaging. Male. Methotrexate / therapeutic use. Methylprednisolone / therapeutic use. Observation. Peptides / therapeutic use. Prevalence. Recurrence

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846110.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Immunosuppressive Agents; 0 / Peptides; 5M691HL4BO / Glatiramer Acetate; 77238-31-4 / Interferon-beta; BZ114NVM5P / Mitoxantrone; MRK240IY2L / Azathioprine; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


28. Liu JX, Liu JL, Wang GJ: [Using real-time polymerase chain reaction to quantitate bcr-abl mRNA]. Ai Zheng; 2006 Nov;25(11):1447-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Using real-time polymerase chain reaction to quantitate bcr-abl mRNA].
  • BACKGROUND & OBJECTIVE: When leukemia patients achieve complete remission after chemotherapy, a few tumor cells still exist in other tissues outside bone marrow, which is called minimal residual disease (MRD), and it is the base of relapse.
  • To cure leukemia, we should not only find MRD in time, but also quantitate MRD for instructing treatment and predicting prognosis.
  • This study was to establish a real-time reverse transcription-polymerase chain reaction (RT-PCR) system to quantitate bcr-abl mRNA.
  • METHODS: bcr-abl mRNA in leukemia cell line K562 was amplified by RT-PCR.
  • T-A clone was used to construct the combined plasmid to be standard template; the standard curve of bcr-abl oncogene was drawn. bcr-abl mRNA in bone marrow samples of 16 chronic myelocytic leukemia (CML) patients was quantitated by this method.
  • CONCLUSIONS: Real-time PCR has high sensitivity, repetition, and specificity.
  • [MeSH-major] Fusion Proteins, bcr-abl / biosynthesis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094919.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


29. Chi ZH, Liu Z, Sun C, Zhao HG, Liu JL: [Expression of lung resistance protein and multidrug resistance protein genes in bone marrow cells of acute leukemia patients and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Oct;11(5):472-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of lung resistance protein and multidrug resistance protein genes in bone marrow cells of acute leukemia patients and its clinical significance].
  • To study the expression of lung resistance protein (LRP) and multidrug resistance protein (MRP) genes in bone marrow cells in patients with acute leukemia and its clinical significance, expression of LRP and MRP mRNA in bone marrow cells from 47 cases of acute leukemia, including 10 refractory or relapsed cases, and 7 normal individuals were determined by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR).
  • LRP mRNA level in newly treated cases of acute myelocytic leukemia and refractory or relapsed cases was significantly higher than that in normal individuals, increased LRP mRNA level has correlation with lower sensitivity to initial chemotherapy and was associated with reduced overall survival rate.
  • Complete remission (CR) rate in LRP positive patients was lower than that in negative cases.
  • In conclusion, the expression of LRP mRNA can predict the treatment outcome and prognosis for acute myelocytic leukemia, prognosis was even worse in LRP and MRP linked expression cases, therefore, LRP was an important resistant factor, determination of LRP and MRP expression can help us to evaluate the prognosis and choose chemotherapy program.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14575539.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoproteins; 0 / RNA, Messenger; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


30. Gorin NC: Autologous stem cell transplantation for adult acute leukemia. Curr Opin Oncol; 2002 Mar;14(2):152-9
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for adult acute leukemia.
  • Autologous stem cell transplantation using marrow or peripheral blood is routinely used to consolidate patients with acute myelocytic leukemia in complete remission.
  • The situation is less clear for adult acute lymphocytic leukemia in which results achieved with all strategies are disappointing.
  • In acute myelocytic leukemia, autografts should be done in patients with good and standard risk factors.
  • Patients with high-risk acute myelocytic leukemia defined by poor cytogenetics or failure to achieve remission with the first induction course, should proceed to allogeneic stem cell transplantation with the best available human leukocyte antigen-identical donor (family or unrelated), and the nature of the conditioning regimen (myelo-ablative or non-myelo-ablative) should be decided in relation to age, and the patient's clinical condition.
  • Results of autografting in acute myelocytic leukemia rely strongly on the quality of the graft.
  • In good-risk acute myelocytic leukemia, autografting is superior to high-dose ARA-C; in standard-risk acute myelocytic leukemia, both are supposedly equivalent.
  • In adult acute lymphocytic leukemia, good-risk patients get the best benefit from autografting over conventional chemotherapy.
  • Maintenance chemotherapy after transplant is likely to bring benefit.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11880704.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


31. Florschütz A, Schumann HJ, Erikson C, Zugehör M, Rosahl W, Schreiber J: [Primary pulmonary manifestation of extramedullary acute myelocytic leukemia]. Pneumologie; 2001 Jun;55(6):302-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary pulmonary manifestation of extramedullary acute myelocytic leukemia].
  • We report on a 49 year old female with primary extra-medullary manifestation of a acute myeloid leukemia in the lungs without leukemic signs.
  • The disease was diagnosed by detection of leukemic blast cells in bronchoalveolar lavage.
  • Chemotherapy with the TAD-VP-scheme resulted in partial remission.
  • To our knowledge this is the first description of primary isolated extra-medullary manifestation of a acute myeloid leukemia in the lungs.
  • [MeSH-major] Bronchoalveolar Lavage Fluid / cytology. Leukemia, Myeloid, Acute / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / pathology. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Middle Aged. Prednisolone / administration & dosage. Thioguanine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11458438.001).
  • [ISSN] 0934-8387
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; FTK8U1GZNX / Thioguanine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


32. Zhang X, Ji L, Liu S, Wang J: Ph-negative acute lymphocytic leukemia occurring after interferon therapy for Ph-positive chronic myelocytic leukemia. Leuk Res; 2003 Apr;27(4):367-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ph-negative acute lymphocytic leukemia occurring after interferon therapy for Ph-positive chronic myelocytic leukemia.
  • We report a unique case of chronic myelocytic leukemia (CML) with the Philadelphia (Ph) chromosome.
  • The patient obtained cytogenetic complete remission (CR) after treatment with interferon (IFN).
  • When he transformed to acute lymphocytic leukemia (ALL), cytogenetic analysis showed that the karyotype was normal and fluorescence in situ hybridization (FISH) indicated that blast cells were Ph-negative.
  • [MeSH-major] Interferon-alpha / administration & dosage. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / genetics. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


33. Choi HW, Shin MG, Sawyer JR, Cho D, Kee SJ, Baek HJ, Kook H, Kim HJ, Shin JH, Suh SP, Hwang TJ, Ryang DW: Unusual type of TLS/FUS-ERG chimeric transcript in a pediatric acute myelocytic leukemia with 47,XX,+10,t(16;21)(p11;q22). Cancer Genet Cytogenet; 2006 Jun;167(2):172-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual type of TLS/FUS-ERG chimeric transcript in a pediatric acute myelocytic leukemia with 47,XX,+10,t(16;21)(p11;q22).
  • We report on a case of pediatric acute myelocytic leukemia showing 47,XX,+10,t(16;21)(p11;q22) that resulted in an unusual TLS/FUS-ERG chimeric transcript.
  • The leukemic cells showed erythrophagocytosis, positive reactions for myeloperoxidase and Sudan black B stains, and negative reactions for periodic acid-Schiff and alpha-naphtyl butyrate esterase stains as well as expression of myeloid antigens.
  • We also confirmed a very rare type of TLS/FUS-ERG chimeric transcript by fusion of the 5' part of the TLS/FUS gene in chromosome 16p11 and the 3' part of the ERG gene in chromosome 21q22 using reverse-transcriptase polymerase chain reaction and direct sequencing.
  • After achieving a complete remission with two cycles of induction chemotherapy, the patient received an umbilical cord blood transplantation.
  • [MeSH-major] Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 21. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. RNA-Binding Protein FUS / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737920.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA-Binding Protein FUS; 0 / TLS-ERG fusion protein, human
  •  go-up   go-down


34. Gonen C, Celik I, Cetinkaya YS, Haznedaroglu I: Cytarabine-induced fever complicating the clinical course of leukemia. Anticancer Drugs; 2005 Jan;16(1):59-62
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytarabine-induced fever complicating the clinical course of leukemia.
  • The aim of this study is to assess the frequency and clinical characteristics of cytosine arabinoside-induced fever in patients with acute myeloid leukemia in remission, receiving high-dose (3 g/m2) consolidation therapy.
  • Median time of onset of fever from the beginning of first chemotherapy dose was 22 h and maximum temperature was in the range 38.0-39.7 degrees C (mean+/-SD: 38.8+/-0.5 degrees C).
  • Our analysis suggests that 'cytarabine fever' is a frequent and often a self-limiting complication of high-dose cytosine arabinoside consolidation therapy, and cost-reductive approaches could be structured based on this background.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Cytarabine / adverse effects. Fever / chemically induced. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613905.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


35. Alvarez M: Intracerebral granulocytic sarcoma. J Neurosci Nurs; 2007 Oct;39(5):297-304
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulocytic sarcomas, also known as chloromas, are rare extramedullary tumors of myeloid or myelocytic origin.
  • They are usually associated with both acute and chronic myelogenous leukemia and myeloproliferative disorders.
  • Leukemia involvement of the central nervous system most commonly presents as meningeal leukemia; intracerebral granulocytic sarcoma (IGS) is rare.
  • Magnetic resonance imaging with and without gadolinium is the imaging of choice to evaluate the tumor; however, tissue biopsy is essential for definitive diagnosis.
  • Treatment usually involves radiation followed by chemotherapy, depending on the previous systemic treatment.
  • Because medical literature about IGS is scarce, optimal treatment is unclear.
  • With the number of leukemia patients in remission, the incidence of IGS is expected to rise.
  • This is because most chemotherapeutic agents do not cross the blood-brain barrier, making the brain a target for leukemia recurrence.
  • Nurses play a vital role in helping patients and families understand the disease process, the treatments involved, and the necessary adjustments, such as performing mundane activities of daily living, especially when neurocognitive impairments are present.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Blood-Brain Barrier. Cerebral Hemorrhage / etiology. Cognition Disorders / etiology. Headache / etiology. Humans. Incidence. Infection / etiology. Leukemic Infiltration. Magnetic Resonance Imaging. Male. Middle Aged. Nurse's Role / psychology. Patient Education as Topic. Prognosis. Radiotherapy, Adjuvant. Rare Diseases. Tomography, X-Ray Computed. Tumor Lysis Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966297.001).
  • [ISSN] 0888-0395
  • [Journal-full-title] The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
  • [ISO-abbreviation] J Neurosci Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Gong H, Liu WL, Zhou JF, Xu HZ: [Expression of mitosis checkpoint gene CHFR in acute leukemia]. Zhonghua Yi Xue Za Zhi; 2005 Apr 27;85(16):1085-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of mitosis checkpoint gene CHFR in acute leukemia].
  • OBJECTIVE: To investigate the expression of mitosis checkpoint gene CHFR in adult patients with acute leukemia (AL) and its clinical significance.
  • METHODS: Four ml of bone marrow was extracted from 65 AL patients, 38 males and 27 females, with the median age of 35, 43 with acute myelocytic leukemia (AML) and 22 with acute lymphocytic leukemia (ALL), 45 de novo patients and 20 recurrent patients, and 8 normal donor of allogeneic bone marrow transplantation as controls.
  • (1) The levels of CHFR protein and mRNA were correlated with the cumulative percentages of cells in S phases. (2) The expression level of CHFR protein in 40.6% (13/32) of the AL patients and that of the CHFR mRNA in 60.0% (27/45) of the AL patients were both significantly lower than those of the normal controls. (3) The mean expression level of CHFR protein in the recurrent acute lymphoblastic leukemia (ALL) was 0.71, significantly higher than that of the de novo group (0.38, t = 2.54, P = 0.017). (4) The complete remission (CR) rates in the AL patients with high expression levels of CHFR protein and mRNA were 30.2% and 42.4% respectively, significantly lower than those in the AL patients with low expression levels (88.6% and 85.4% respectively, both P < 0.05).
  • CONCLUSION: By affecting mitotic checkpoint function, CHFR inactivation plays a key role in tumorigenesis in adult patients with acute leukemia.
  • Moreover, the aberrant expression of CHFR appears to be a good molecular marker to predict the sensitivity of acute leukemia to chemotherapy.
  • [MeSH-major] Cell Cycle Proteins / biosynthesis. Leukemia, Myeloid, Acute / genetics. Neoplasm Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Cell Cycle. Child. Drug Resistance. Female. HL-60 Cells. Humans. Male. Middle Aged. Mitosis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029562.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


37. Xu WL, Jin J, Chen ZM, Lou JY, Yu YB: [Clinical and experimental study of 38 cases with trisomy 8]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Dec;20(6):528-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Thirty-two of 38(84.2%) cases with trisomy 8, and fourteen of 17(82.4%) cases with trisomy 8 as the sole chromosome aberration were myeloid disorders such as myelodysplastic syndrome (MDS), acute myelocytic leukemia (AML), chronic myelocytic leukemia (CML).
  • The incidence of trisomy 8 was higher in myeloid disease than in lymphocytic disease (5% vs 1.3%); the incidence of trisomy 8 was higher in acute monocytic leukemia than in other AML (6.1% vs 2.4%), and the incidence of trisomy 8 in chronic myelomonocytic leukemia( CMML) was higher than that in other myelodysplastic syndrome (MDS) (25% vs 13.2%); 17 cases had trisomy 8 as the sole chromosome aberration, 21 cases had other additional chromosome aberrations.
  • Eleven cases were treated with chemotherapy, among them only 10 cases data were available.
  • Seven cases acquired complete remission but 3 of them were M3, the other 3 cases had no response after two courses of chemotherapy.
  • CONCLUSION: Trisomy 8 may play an important role in the pathogenesis and progression of the hematological disease, especially myeloid disease.
  • [MeSH-major] Chromosomes, Human, Pair 8. Leukemia / genetics. Myelodysplastic Syndromes / genetics. Trisomy

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14669224.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


38. Liu L, Yang L, Zhang Y, Xu ZF, Yu MH, Wang JX, Xiao ZJ: [Polymorphisms of RAD51(G135C) and XRCC3(C241T) genes and correlations thereof with prognosis and clinical outcomes of acute myeloid leukemia]. Zhonghua Yi Xue Za Zhi; 2008 Feb 5;88(6):378-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polymorphisms of RAD51(G135C) and XRCC3(C241T) genes and correlations thereof with prognosis and clinical outcomes of acute myeloid leukemia].
  • OBJECTIVE: To investigate the impacts of RAD51G(135C) and XRCC3(C241T) genotypes on the response, adverse effects, and prognosis of acute myelocytic leukemia (AML).
  • The Complete remission (CR) rate, adverse effects, overall survival (OS), and relapse-free survival (RFS) were compared among the groups with different genotypes. RESULTS:.
  • (1) During the induction chemotherapy, XRCC3(C241T) polymorphic allele was significantly associated with the shorter survival of the AML patients with t (15; 17)/PML-RARalpha (OR = 8.750, P = 0.046).
  • Among the non-M3 patients, the complete remission (CR) rate of those with double RAD51(G135C) and GSTT1 wild genotypes was 71.6%, significantly higher than that of those not with double RAD51(G135C) and GSTT1 wild genotypes (54.4%, P = 0.028). (2) The OS of the non-M3 AML patients with double RAD51(G135C) and GSTT1 wild genotypes was (39.1 +/- 7.1) months, significantly longer than those with double variant types [(22.4 +/- 3.2) months, P = 0.042].
  • The relapse-free survival (RFS) of the M4EO and M2 patients with double XRCC3(C241T) and GSTT1 wild type genotype were 48.3 months and 56.5 months, both significantly longer than those of the patients with double variant genotypes (28.8 months and 10.0 months respectively, both P < 0.05).
  • The RFS of the M2 patients with triple RAD51(G135C), GSTT1, and GSTM1 variant genotypes was 10.0 months, significantly shorter than that of the patients with triple RAD51(G135C), GSTT1, and GSTM1 wild genotypes (64.2 months, P = 0.015). (3) The risk levels of neutropenia, nausea and vomiting, and alopecia of the patients with variant XRCC3(C241T) genotype were all significantly higher than those of the wild type genotype (all P < 0.05).
  • CONCLUSION: The polymorphisms of XRCC3(C241T) and RAD51(G135C) genes are significantly related to response to therapy, adverse effects, and prognosis of AML.
  • Detection of the XRCC3(C241T) and RAD51(G135C) genotypes may be useful in selecting individual chemotherapy regimens for patients with AML.
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Polymorphism, Genetic. Rad51 Recombinase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Alleles. Child. Child, Preschool. Female. Follow-Up Studies. Gene Frequency. Genotype. Humans. Male. Middle Aged. Prognosis. Remission Induction. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581889.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 3; EC 2.7.7.- / Rad51 Recombinase
  •  go-up   go-down


39. Savranlar A, Ustündag Y, Ozer T, Bayraktaroglu T, Demircan N, Ozdemir H, Borazan A: A thoracic-epidural granulocytic sarcoma case that was diagnosed preceding the onset of and that recurred co-incidental to acute promyelocytic leukemia, which developed after surgical treatment. Acta Med Okayama; 2004 Oct;58(5):251-4
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A thoracic-epidural granulocytic sarcoma case that was diagnosed preceding the onset of and that recurred co-incidental to acute promyelocytic leukemia, which developed after surgical treatment.
  • Granulocytic sarcoma or chloroma is a tumor seen in myelocytic leukemia.
  • Spinal epidural onset is rare and is generally seen before or together with the onset of myelocytic leukemia.
  • At this time, an epidural mass at the 6th-9th thoracic levels was detected on magnetic resonance imaging, and acute promyelocytic leukemia was diagnosed.
  • After systemic chemotherapy, partial remission was achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epidural Space. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasm Recurrence, Local. Neoplasms, Second Primary. Sarcoma, Myeloid / surgery. Spinal Neoplasms / diagnosis. Thoracic Vertebrae
  • [MeSH-minor] Adolescent. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15666994.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


40. Izumi N, Kumagai H, Shindo T: [An autopsy case of pulmonary mucormycosis with fatal hemoptysis from a rupture of the thoracic descending aorta during remission from acute myelocytic leukemia]. Rinsho Ketsueki; 2000 Nov;41(11):1201-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsy case of pulmonary mucormycosis with fatal hemoptysis from a rupture of the thoracic descending aorta during remission from acute myelocytic leukemia].
  • After failure of initial remission induction therapy, she was successfully treated with the MEC regimen as a second-line chemotherapy.
  • On June 22, the first consolidation therapy was started.
  • One week later, the patient developed a high fever with backache.
  • Chest computed tomography (CT) on July 8 showed a 3cm mass lesion adjacent to the thoracic descending aorta in the left upper lobe.
  • She was given fluconazole and antibiotics, and remained in remission.
  • [MeSH-major] Aortic Aneurysm, Thoracic / etiology. Aortic Rupture / etiology. Hemoptysis / etiology. Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / complications. Mucormycosis / complications
  • [MeSH-minor] Adolescent. Female. Humans. Remission Induction

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193440.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 15
  •  go-up   go-down


41. Telek B, Batár P, Udvardy M, László R: [Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature]. Orv Hetil; 2006 May 7;147(18):827-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature].
  • Chronic neutrophilic leukemia is an uncommon hematological entity.
  • In the last 20 years seven patients have been diagnosed with chronic neutrophilic leukemia at our department.
  • All but one had splenomegaly, two patients developed severe anaemia and in one case thrombocytosis was present at the time of diagnosis.
  • White blood cell count ranged between 39 x 10(9)/1-71 x 10(9)/l with 80% of neutrophils and striking myeloid hyperplasia were present in the bone marrow without evidence of any dysplasia resembling chronic myelocytic leukemia.
  • Three of them died due to progression of chronic neutrophilic leukemia.
  • One patient, initially receiving hydroxyurea + interferon therapy and showing progression, developed complete hematological remission with an eight week imatinib mesylate (Glivec) treatment.
  • Beside of their own experiences the authors review the current literature and discuss differential diagnostic and therapeutic challenges, as well.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Neutrophilic, Chronic / diagnosis. Leukemia, Neutrophilic, Chronic / drug therapy
  • [MeSH-minor] Aged. Benzamides. Diagnosis, Differential. Humans. Hungary. Hydroxyurea / administration & dosage. Imatinib Mesylate. Interferons / administration & dosage. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Male. Middle Aged. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Retrospective Studies. Splenomegaly / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Neutrophilic Leukemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784137.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; 9008-11-1 / Interferons; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


42. Estey E: Reducing mortality associated with immediate treatment complications of adult leukemias. Semin Hematol; 2001 Oct;38(4 Suppl 10):32-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing mortality associated with immediate treatment complications of adult leukemias.
  • Analysis of data from 806 patients with newly diagnosed adult acute myelocytic leukemia (AML) (not including acute promyelocytic leukemia [APL] patients) treated at M.D.
  • Anderson Cancer Center from 1995 through 1999 indicated that among patients entering a particular week of induction therapy, mortality rates were 6%, 8%, 6%, 9%, and 6% during weeks 1 to 2, 3 to 4, 5 to 6, 7 to 8, and 9 to 10, respectively.
  • Because the mortality rate was not higher in the period immediately after treatment began, a definition of the period covered by the term "immediate" is somewhat arbitrary rather than "biologic," as might be the case if the early weeks were distinguished by a particularly high mortality rate. M.D.
  • Anderson researchers have focused on the treatment complications and deaths occurring in the first 4 weeks after the beginning of induction therapy.
  • Anderson analysis of pheresis (146 patients with WBC > 50,000 +/- microL) suggest that the value of this procedure is questionable.
  • Anderson are examining the role of intravenous itraconazole, which produces higher concentrations than itraconazole capsules in prophylaxis, and the role of FK 463 in treatment of fungal infections.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / mortality
  • [MeSH-minor] Adult. Biomarkers / blood. Cause of Death. Humans. Infection / drug therapy. Infection / etiology. Infection / mortality. Leukocyte Count. Prognosis. Remission Induction. Retrospective Studies. Risk Factors. Time Factors. Tumor Necrosis Factor-alpha / metabolism. Uric Acid / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11694950.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Tumor Necrosis Factor-alpha; 268B43MJ25 / Uric Acid
  •  go-up   go-down


43. Van Den Neste E, Michaux L, Layios N, Costantini S, Francart J, Lambert C, Sonet A, André M, Robert A, Ferrant A: High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol; 2004 Jun;83(6):356-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnoses were chronic lymphocytic leukemia (CLL) in 15, Waldenström's macroglobulinemia in 4, mantle cell lymphoma in 6, follicular non-Hodgkin's lymphoma (NHL) in 10, and other low-grade NHL in 3 patients.
  • The response rate was 51% [complete remission (CR): 14%, partial remission (PR): 38%].
  • In 12 (32%) patients, autoimmune manifestations developed requiring treatment in most of them.
  • Second cancers arose in five (13%) patients (myelodysplastic syndrome/acute myelocytic leukemia in three, lung cancer in two).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoproliferative Disorders / complications. Lymphoproliferative Disorders / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15024607.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


44. Niitsu N, Ishii Y, Matsuda A, Honma Y: Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine. Cancer Res; 2001 Jan 1;61(1):178-85
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
  • Since the establishment of all-trans retinoic acid (ATRA) differentiation therapy, the prognosis of acute promyelocytic leukemia (APL) has improved, and APL has become a curable subtype of acute myelocytic leukemia.
  • Complete remission can be achieved with ATRA alone, but disease-free survival is still too short because of relapse.
  • However, growth of the APL cell lines NB4 and HT93 is less sensitive to araC than to that of other myeloid leukemia cell lines such as HL-60 and U937.
  • The ATRA-induced differentiation of NB4 cells was not augmented by araC, whereas combined treatment with ATRA and DMDC had more than additive effects in inducing the differentiation of NB4 cells.
  • Similar results were observed in a primary culture of leukemia cells that had been freshly isolated from APL patients.
  • These results suggest that DMDC may play a role in the treatment of APL.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Deoxycytidine / pharmacology. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Cell Differentiation / drug effects. Cell Division / drug effects. Cytarabine / analogs & derivatives. Cytarabine / pharmacokinetics. Cytarabine / pharmacology. Cytidine Deaminase / metabolism. Drug Resistance, Neoplasm. Drug Synergism. Female. Growth Inhibitors / pharmacology. HL-60 Cells / cytology. HL-60 Cells / drug effects. Humans. Male. Middle Aged. Tretinoin / pharmacology. Tumor Cells, Cultured / drug effects. U937 Cells / cytology. U937 Cells / drug effects

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11196157.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Growth Inhibitors; 04079A1RDZ / Cytarabine; 0W860991D6 / Deoxycytidine; 119804-96-5 / 2'-methyl-2'-deoxyidenecytidine; 5688UTC01R / Tretinoin; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


45. Hamaki T, Kami M, Momomura S, Mineishi S, Kusumi E, Kanda Y, Ueyama J, Miyakoshi S, Morinaga S, Takaue Y, Mutou Y: Sustained molecular remission in a patient with CML in blastic crisis receiving dose-reduced hematopoietic stem-cell transplantation followed by early withdrawal of cyclosporine and prophylactic use of interferon-alpha. Am J Hematol; 2002 Nov;71(3):196-9
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained molecular remission in a patient with CML in blastic crisis receiving dose-reduced hematopoietic stem-cell transplantation followed by early withdrawal of cyclosporine and prophylactic use of interferon-alpha.
  • A 54-year-old man with chronic myelocytic leukemia in blastic phase received reduced-intensity transplantation (RIST) from an HLA-identical unrelated donor.
  • To induce GVHD and augment a graft-versus-leukemia effect, we initiated interferon-alpha therapy on day 80 to a maximum dosage of three million units five times a week.
  • He achieved molecular remission on day 94 followed by the development of extensive chronic GVHD the severity of which paralleled to the dose of interferon-alpha GVHD gradually subsided after discontinuation of interferon-alpha and the patient remains in molecular remission 18 months after transplantation.
  • This case suggests that early withdrawal of cyclosporine and the prophylactic use of interferon-alpha are promising in RIST for high-risk leukemia.
  • [MeSH-major] Blast Crisis / surgery. Cyclosporine / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Immunosuppressive Agents / administration & dosage. Interferon-alpha / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Drug Administration Schedule. Graft vs Host Disease / physiopathology. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12410575.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Interferon-alpha; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


46. Naithani R, Kumar R, Mahapatra M, Agrawal N, Mishra P: Early discharge from hospital after consolidation chemotherapy in acute myeloid leukemia in remission: febrile neutropenic episodes and their outcome in a resource poor setting. Haematologica; 2008 Sep;93(9):1416-8
MedlinePlus Health Information. consumer health - Health Facilities.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early discharge from hospital after consolidation chemotherapy in acute myeloid leukemia in remission: febrile neutropenic episodes and their outcome in a resource poor setting.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fever. Hospitals. Leukemia, Myeloid, Acute / drug therapy. Neutrophils / cytology. Patient Discharge / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Leukocyte Count. Male. Middle Aged. Remission Induction. Treatment Outcome


47. Bilgrami S, Edwards RL, Bona RD, Kazierad D, Furlong F, Fox J, Clive J, Naqvi BH, Tutschka PJ: A pilot study of busulfan, cyclophosphamide and etoposide followed by autologous transplantation for acute myeloid leukemia in remission. Acta Haematol; 2000;104(2-3):144-7
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of busulfan, cyclophosphamide and etoposide followed by autologous transplantation for acute myeloid leukemia in remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Busulfan / administration & dosage. Busulfan / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Male. Middle Aged. Pilot Projects. Recurrence. Remission Induction. Transplantation, Autologous

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11154994.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan; BuCEt protocol
  •  go-up   go-down


48. Khouri S, Kotliroff A, Lishner M, Amital H: Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission. Isr Med Assoc J; 2008 Apr;10(4):320-1
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
  • [MeSH-major] Agranulocytosis / chemically induced. Antineoplastic Agents / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / adverse effects. Protein Kinase Inhibitors / adverse effects. Pyrimidines / adverse effects

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18548994.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down






Advertisement